SCHEMBL1534075

SCHEMBL1534075

CC(C(=O)O)c1nc(-c2ccccc2)c(-c2ccccc2)o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 19/20 0.59
RXRA P19793 6/20 0.59
KDM4E B2RXH2 2/20 0.52
LMNA P02545 2/20 0.52
ALDH1A1 P00352 1/20 0.52
RXRB P28702 5/20 0.51
RXRG P48443 3/20 0.51
NR4A1 P22736 3/20 0.51
NR4A3 Q92570 3/20 0.51
POLB P06746 1/20 0.49
ABCC4 O15439 1/20 0.49
C5 P01031 1/20 0.49
CHRM2 P08172 1/20 0.49
CYP3A4 P08684 1/20 0.49
CHRM1 P11229 1/20 0.49
DRD2 P14416 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
TBXA2R P21731 1/20 0.49
PTGS1 P23219 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9428091 0.93 NR4A2 (0.53) NR4A2RXRAKDM4ELMNAALDH1A1
SCHEMBL9428401 0.89 NR4A2 (0.50) NR4A2RXRAKDM4ELMNAALDH1A1
SCHEMBL6000535 0.88 PTGS2 (0.63) NR4A2RXRAKDM4ELMNAALDH1A1
SCHEMBL5823861 0.87 PTGS2 (0.50) NR4A2RXRALMNACYP3A4CHRM1
SCHEMBL6002469 0.87 PTGS2 (0.50) NR4A2RXRALMNACYP3A4CHRM1
SCHEMBL9455476 0.85 NR4A2 (0.58) NR4A2RXRAKDM4ELMNAALDH1A1
SCHEMBL11150444 0.85 NR4A2 (0.45) NR4A2RXRAKDM4ELMNAALDH1A1
SCHEMBL10797572 0.84 PPARD (0.45) NR4A2RXRAKDM4ELMNAALDH1A1
SCHEMBL27638570 0.82 CYP1A2 (0.43) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL10260877 0.82 NR4A2 (0.55) NR4A2RXRAKDM4ELMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879891-A1 MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY Nycomed GmbH (DE) 2008-01-23 EP claimed
EP-1877410-A1 MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY Nycomed GmbH (DE) 2008-01-16 EP claimed
WO-2006117315-A1 MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECCTIVE ACTIVITY NYCOMED GMBH (DE) 2006-11-09 WO claimed
WO-2006117316-A1 MUTUAL PRODRUG COMPOUNDS FOR USE US ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY NYCOMED GMBH (DE) 2006-11-09 WO claimed
US-20060154954-A1 Combinations and use of selected pharmaceutically active compounds ALTANA PHARMA AG (DE) 2006-07-13 US claimed
EP-1599175-A2 IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS ALTANA Pharma AG (DE) 2005-11-30 EP claimed
WO-2005074930-A1 PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS ALTANA PHARMA AG (DE) 2005-08-18 WO claimed
WO-2004071391-A2 IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS ALTANA PHARMA AG (DE) 2004-08-26 WO claimed
CN-116570566-A Olsaprazine solid dispersion, preparation and preparation method thereof 东南大学 2023-08-11 CN disclosed
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS TECHFIELDS PHARMA CO., LTD (CN) 2023-07-27 US disclosed
US-11541029-B2 High penetration compositions and their applications TECHFIELDS PHARMA CO., LTD. (CN) 2023-01-03 US disclosed
US-11390868-B2 Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity CURNA, INC. (US) 2022-07-19 US disclosed
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO LTD (CN) 2021-11-18 US disclosed
CN-113636965-A High penetration composition and application thereof 于崇曦 2021-11-12 CN disclosed
EP-0111456-A1 Analgesic combinations Cooper, Stephen A. Dr. (US) 1984-06-20 EP disclosed
US-4455298-A MOLLUSC EXTRACT MCFARLANE STUART J (NZ) 1984-06-19 US disclosed
EP-0010061-B1 PHARMACEUTICAL PREPARATIONS CONTAINING A MOLLUSC EXTRACT Mc Farlane, Stuart John (NZ) 1983-07-13 EP disclosed
EP-0034270-A1 Combinations of agents which give enhanced anti-inflammatory activity AMERICAN CYANAMID COMPANY (US) 1981-08-26 EP disclosed
WO-1980000661-A1 PHARMACEUTICAL PREPARATIONS CROFT J (NZ) 1980-04-17 WO disclosed
EP-0010061-A1 Pharmaceutical preparations containing a mollusc extract Mc Farlane, Stuart John (NZ) 1980-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES NR4A2 896/4885RXRA 610/4885KDM4E 4795/4885
US-11541029-B2 High penetration compositions and their applications SLC19A1, HIRA, SLC43A1 NR4A2 1676/4885RXRA 1691/4885KDM4E 4307/4885
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS SLC5A7, SLC19A1, SLC43A1 NR4A2 2109/4885RXRA 1969/4885KDM4E 2401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.